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Managing women with gestational diabetes mellitus
in the postnatal period
Catherine Kim
Departments of Medicine and Obstetrics & Gynecology, University of Michigan, Ann Arbor, MI, USA
Guidelines for management of women with a history of gestational diabetes mellitus (GDM) in the postpregnancy period have lagged
behind the recognition that this is an important time for medical intervention. However, in the past decade, the evidence-base for screening
algorithms, contraceptive management, diabetes prevention strategies and implications for offspring has expanded. In this review, we discuss
current recommendations for managing women with GDM in the postnatal period, with particular attention to postpartum diabetes screening,
prevention of future glucose intolerance and family planning.
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Introduction
For half a century, the strong association between gestational
diabetes mellitus (GDM), or glucose intolerance first
recognized during pregnancy and postpartum maternal glucose
intolerance has been acknowledged [1]. In a 1991 review, John
B. O’Sullivan observed: ’Although the variability in diabetes
incidence rates is wide, there is broad general agreement on
the predictive nature of gestational blood glucose levels’ [2],
a statement that still holds. In a recent meta-analysis, GDM
conferred a sevenfold risk for future maternal diabetes [3], and
up to one-third of women with diabetes may have been affected
by prior GDM [4]. GDM women’s greater risk for postpartum
glucose intolerance also includes risk for another episode of
GDM [5].
Guidelines for management of this risk have lagged behind
its recognition. Several factors may have interfered with
studies to guide management. These factors include: the
long length of time elapsed between GDM and incident
future diabetes, the management of GDM and postpartum
diabetes by different medical providers, and the traditional
focus on fetal as opposed to maternal outcomes. However, in
the past decade, the evidence-base for screening algorithms,
contraceptive management, diabetes prevention strategies and
implications for offspring has expanded. In this review, I discuss
current recommendations for managing women with GDM in
the postnatal period, with particular attention to postpartum
diabetes screening, prevention of future glucose intolerance
and family planning.
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Postpartum Screening
According to cohort studies from Latina (Hispanic) popula-
tions in the USA, approximately 10% of women diagnosed with
GDM had unrecognized preconception diabetes [6]. Postpar-
tum glucose screening in the early postnatal period will detect
these women. Later screening will detect women who eventu-
ally do develop elevated fasting and/or postchallenge glucose
levels [7], despite initial normal fasting and postchallenge glu-
cose levels. Although the time of initial postpartum screening
is usually recommended at 6 weeks to coincide with the first
postpartum visit [8–14], glucose may normalize much earlier
after the delivery of the placenta, and screening before 6 weeks
but after delivery might increase diabetes screening rates in
recent gravidas [8].
Recommendations for postpartum diabetes screening for
GDM women vary between medical organizations. The primary
debate revolves around whether screening should consist of
performance of a postpartum fasting glucose alone vs. a 75-g
oral glucose tolerance test (OGTT). As of the time of the writing
of this review, no organizations endorse the haemoglobin A1c
(HbA1c) for diabetes screening, although this may change with
the recent emphasis by the American Diabetes Association
(ADA) upon the value of the HbA1c for screening. As of
2008, the UK-based National Institute for Health and Clinical
Excellence (NICE) recommends a postpartum fasting glucose
only, specifically without the OGTT [8]. The 2007 Fifth-
International Workshop Conference on GDM recommended
that a 75-g OGTT be performed at≥ 6 weeks postpartum [9]. In
2009, the American College of Obstetricians and Gynecologists
stated that screening should be performed and notes that the
OGTT demonstrates greater sensitivity than the fasting glucose,
but that fasting glucose is acceptable [10], a contrast with its
previous agnostic recommendations regarding screening. The
diabetes screening guidelines of other medical organizations
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adopt the guidelines for general at-risk populations. The
1999/2006 World Health Organization (WHO) guidelines
recommend a 75-g OGTT [11,12]. The 1997/2003 ADA
guidelines recommend a fasting glucose in general practice,
although the guidelines recognize the OGTT as a valid
diagnostic method [13,14].
The differences between medical organizations are because of
disagreement regarding the importance of the greater sensitivity
of the OGTT vs. its lower reliability, greater inconvenience and
cost. Women may have defects in fasting glucose, postchallenge
glucose, or both [15]; therefore, the OGTT will detect more
glucose intolerant persons than the fasting value alone. In the
general US population in the National Health and Examination
Survey III, 44% of adults ≥ 40 years with either abnormal
fasting or 2-h glucose values met both the fasting and 2-h
glucose criteria [16]. Fourteen per cent met the fasting criteria
but not the 2-h criteria, and fourty-one per cent met the 2-h
criteria alone [16]. In the Diabetes Epidemiology: Collaborative
analysis of Diagnostic criteria in Europe (DECODE) study, also
a general population, only 28% of participants with impaired
fasting glucose (IFG) or elevated 2-h values met both criteria
and 31% met the 2-h criteria only [17]. However, the greater
sensitivity of the OGTT is offset by the greater variability in the
2-h glucose level compared with the fasting glucose [18]. The
day-to-day intraindividual coefficients of variation range from
6.4 to 11.4% for fasting glucose and 14.3–16.7% for the 2-h
glucose among the general population [18,19]. In addition, the
OGTT has greater initial cost and inconvenience, drawbacks
cited by the ADA and NICE. In one study, almost 20% of
women declined a postnatal GTT presumably because of its
relatively lower acceptability [20].
Although organizations differ as to whether or not to obtain
the 2-h glucose, the cut-offs for diabetes are similar across
groups: fasting glucose of 7.0 mmol/l or 126 mg/dl and, if
obtained, a 2-h glucose of 11.1 mmol/l or 200 mg/dl after a 75-
g challenge. The fasting glucose value of 126 mg/dl was chosen
because of its threshold association with retinopathy [21].
The 2-h criterion of 200 mg/dl corresponded with both all-
cause and cardiovascular disease mortality, as well as providing
roughly the same risk as a fasting glucose of 126 mg/dl [21].
Impaired glucose regulation (IGR) consists of IFG and/or
impaired glucose tolerance (IGT). The ADA defines IFG as
a fasting glucose level ≥ 100 mg/dl or 5.6 mmol/l [14] and
the WHO defines IFG as a fasting glucose level >110 mg/dl
or 6.1 mmol/l [12]. The ADA defines IGT as a 2-h glucose
140–199 mg/dl or 7.8–11.0 mmol/l, as does the WHO. The
IFG cut-off was chosen based on review of receiver operator
curves for diabetes prediction and the disagreement between
ADA and WHO was based on whether receiver operator curves
should be the basis for cut-offs [12,14]. The IGT cut-off was
initially chosen more arbitrarily, although the 2-h glucose
does correspond with cardiovascular mortality and future
diabetes [12,14].
Several issues unique to women with recent GDM
could potentially influence choice of screening test in
this population. However, the influence of these issues is
speculative and their impact has not been formally examined.
First, women with recent GDM might benefit from more
sensitive screening strategies, because diabetes poses risk to
future pregnancies. Specifically, this risk includes congenital
anomalies of cardiac malformations, neural tube defects and
limb dysgenesis. All are strongly associated with glucose
levels before conception [22]. Second, women with GDM
are, on average, approximately 10–20 years younger than
other populations diagnosed with glucose intolerance [23,24].
Women with GDM who develop diabetes face relatively
prolonged dysglycaemia, which could potentially place them
at higher risk for diabetes complications than the general
population. Earlier identification with more sensitive screening
could lead to reduction of complications. In the Diabetes
Control and Complications Trial and its follow-up, intensive
treatment reduced microvascular complications, with effects
persisting after discontinuation of the trial [25]. In statistical
models, the postpartum OGTT is generally more advantageous
among women with recent GDM if diabetes identification is the
endpoint [26]. Finally, because the glucose test results may also
be used to determine the presence of IGR or ‘prediabetes’ [11],
earlier identification of IGR using the OGTT may lead to earlier
prevention efforts.
Prevention of Maternal Glucose Intolerance
Two influential studies have sparked interest in diabetes
prevention in the GDM population by examining diabetes
prevention intervention among glucose intolerant adults.
The Diabetes Prevention Program (DPP) [27], a multicentre
randomized controlled trial, and the Finnish Diabetes
Prevention Study [28], another large randomized controlled
trial, allocated participants with IGT to intensive lifestyle
interventions. The DPP also randomized participants to daily
metformin. Both studies demonstrated that these interventions
successfully delayed or prevented diabetes [27,28].
One of the recruitment criteria for the DPP was a history of
GDM, and in a subanalysis, intervention effectiveness was
compared between women with and without histories of
GDM [29,30]. Women with histories of GDM enrolled in
the placebo or control arm had a higher cumulative incidence
of diabetes than parous women without histories of GDM, 38%
vs. 26% [29]. Although metformin and lifestyle changes both
reduced diabetes risk among GDM and non-GDM women,
metformin and lifestyle had similar effectiveness in GDM
women (53% vs. 50%), whereas lifestyle changes were more
effective in non-GDM women and the overall cohort (58% vs.
31%) [30]. The reason for the reduced effectiveness of lifestyle
among GDM women was their difficulty with maintaining
weight losses over the 3-year study period. Although reasons
are speculative, GDM women may have had more difficulty
adhering to the demanding lifestyle changes; goals in the DPP
were a 7% weight reduction through diet and physical activity,
with physical activity goals set at 150 min per week of moderate
physical activity [27].
These subanalyses suggest that women with a GDM history
from over a decade ago would benefit from metformin or
lifestyle changes. Some factors may limit implementation in
the general GDM population. GDM women in the DPP were
on average, over 40 years old, greater than the average age of
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the majority of GDM women in the immediate postpartum
period [31]. Moreover, the randomized trial probably selected
for a highly motivated group of participants that did not face or
faced reduced barriers to implementation of lifestyle changes.
Although other studies have demonstrated that lifestyle changes
are possible in the several years postpartum [32–34], these
studies have been small, focused on weight reduction, and did
not examine glucose tolerance.
Other studies have explored the use of pharmacologic agents
to prevent diabetes in GDM women. In the Troglitazone in
Prevention of Diabetes (TRIPOD) study, women with GDM
in the past 4 years were randomized to receive troglitazone,
a thiazolidinedione, or placebo [35]. Troglitazone reduced the
cumulative incidence of diabetes compared to placebo (5.4% vs.
12.1%), but troglitazone has since been discontinued because
of reports of hepatotoxicity [35]. Although pioglitazone
may also have similar effects [36], the safety profile of
the thiazolidinediones regarding future cardiovascular and
osteoporotic disease may limit their use for diabetes prevention.
Although women with GDM are at risk for future episodes
of GDM, few studies have examined whether interventions
can successfully modify this risk. In one study of overweight
women, a low-intensity walking program during pregnancy
led to decreased glucose values during a prenatal OGTT, but
this study was limited by lack of a control group and small
sample size (n = 23) [37]. One ongoing study conducted in
Western Massachusetts by Lisa Chasan-Taber and colleagues is
randomizing pregnant high-risk women to a physical activity
intervention with the aim of reducing risk for GDM (Chasan-
Taber, personal communication); the intervention aims to
increase exercise and also aims to identify serum biomarkers
that may assess in future risk stratification.
Postpartum Contraception, Including
Breastfeeding
As GDM women are by definition of child-bearing age, family
planning is a key issue in postpartum period. Pregnancy itself
may be diabetogenic for GDM women through weight gain
or other hormonal factors [38], with an increase in relative
risk for diabetes between 2 and 3 [39]. Therefore, if family
planning is desired by the GDM woman, prevention of
further pregnancy will prevent both another GDM pregnancy
as well as reduce diabetes risk [38]. Several contraceptive
strategies may influence diabetes risk, particularly in GDM
women. The following section reviews these strategies, which
include the lactation amenorrhoea method (LAM) and
hormonal contraceptive methods. Other methods, such as
barrier contraception and intrauterine devices (IUDs), have
similar effectiveness in postpartum GDM women as in other
populations and do not appear to influence diabetes risk.
LAM has effectiveness rates comparable with birth
control pills and other common and effective methods of
contraception [40]. Moreover, breastfeeding has the added
benefit of decreasing weight [41], itself a risk factor for future
diabetes. Although breastfeeding may also affect glucose levels
independent of weight [42], the impact upon maternal diabetes
incidence has not yet been proven. Among GDM women, two
studies have examined the association between breastfeeding in
the immediate postpartum and future diabetes and did not find
associations, although these results may have been limited by
lack of diabetes screening in all participants [43,44]; similarly,
the lack of association between breastfeeding and diabetes in the
Nurses Health cohort may have also been because of under-
ascertainment [45]. Interestingly, more studies support that
breastfeeding may reduce diabetes incidence among offspring,
as opposed to diabetes incidence in mothers [46–48].
However, to practice LAM effectively, women must
begin breastfeeding immediately after delivery, avoid any
supplementation and breastfeed at least every 4 h during the
daytime and every 6 h during the night [49]. If women begin
menstruating or supplementing earlier, the effectiveness of
LAM decreases dramatically [49]; theoretically, women might
conceive after ovulation but before their first menstrual period
and might now know they were more susceptible to pregnancy.
In addition, the effectiveness of LAM is limited after the
6 months after delivery, at which time another method must
be initiated [49]. Because of these potential difficulties with
implementation, the use of condoms in conjunction with LAM
may decrease contraceptive failure rates.
Hormonal methods, including combination oral contracep-
tives, have comparable effects on glucose tolerance in women
affected and not affected by GDM [50,51], although these com-
parisons were limited by small numbers of participants. Impact
of any hormonal contraceptive method upon glucose tolerance
appeared to be minimal in several small randomized controlled
trials [52] and in one larger prospective study compared to
no hormonal contraception [53]. Of the hormonal contracep-
tives, combination oral contraceptives or oestrogen–progestin
birth control pills are the most popular [54]. The choice of
oestrogen–progestin pill affects glucose metabolism in glu-
cose intolerant women in individual studies, although studies
conflict regarding the optimal progestin [52].
Because of the birth control pill requirement for daily
ingestion, and the associated reduction in effectiveness because
of missing pills, other oestrogen–progestin hormonal methods
have been developed that do not require daily ingestion.
The contraceptive vaginal ring is a flexible ethinyl vinyl
acetate ring which releases ethinyl estradiol and the progestin
etononorgestrel continuously [55]. Absorption is dependent
upon contact with vaginal mucosae, and the ring does not need
to be placed in a particular location, like the diaphragm. Impact
on glucose appears to be minimal [55]. The contraceptive patch
relies on a transdermal delivery system, which releases ethinyl
estradiol and the progestin norelgestromin continuously [56].
The patch releases higher doses of ethinyl estradiol than low-
dose birth control pills, and for this reason may be less desirable
than other effective delivery methods with lower oestrogen
release; however, the patch does not appear to adversely affect
glucose tolerance [57].
Progestin-only pills may have reduced effectiveness com-
pared to their combination oestrogen–progestin counter-
parts [58], but these pills are still popular in the early
postpartum period because they are not thought to alter milk
supply [58]. In addition, progestin-only pills are thought to
have less effects on blood pressure and coagulation risk [58].
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However, the use of a progestin-only pill in combination with
breastfeeding increased risk of conversion to type 2 diabetes
among Latinas with histories of GDM [53]. Although explana-
tions are speculative, lactation may be a relatively progestogenic
state [53], and women at high risk for glucose intolerance may
be particularly vulnerable to the insulin resistance in this state.
Long-acting progestin methods may have even larger effects
on carbohydrate metabolism. Depot medroxyprogesterone
acetate (Depo Provera, Pfizer; New York, NY, USA), or
medroxyprogesterone delivered intramuscularly every 13
weeks, is a highly effective method of contraception, in
part because it does not require daily ingestion of a
pill [56]. However, Depo Provera may increase diabetes risk
in populations at high risk, such as Navajo women [59]
and Latinas [60] with histories of GDM who had abnormal
triglycerides or who were breastfeeding. These effects could
potentially be mediated by increases in adipose tissue
associated with Depo Provera use and possibly through
insulin secretion [61]. Newer progestin-only methods include
Implanon (Schering; Kenilworth, NJ, USA), an etonogestrel
implant. Although the doses of progestin are relatively low,
no carbohydrate metabolism studies examine the implant
during breastfeeding or by triglyceride status. Therefore, in
the absence of other contraindications to oestrogen, progestin-
only methods are not first-line choices for women with histories
of GDM.
If the GDM woman does not anticipate conceiving
in the few years after the postpartum, IUDs are highly
effective methods that do not appear to adversely affect
glucose metabolism, although no studies have been conducted
among GDM women [62]. The copper IUD (TCu380A) and
the levonorgestrel-releasing IUD are the most commonly
used [62]. The different side effect profiles may cause
selection of one over the other; copper IUDs can extend the
menstrual period and associated menstrual cramping, whereas
levonorgestrel IUDs may lead to amenorrhoea and a delay
in return to fertility. If women desire permanent sterilization,
vasectomy is easy to perform, has little morbidity, and obviously
does not adversely affect women’s metabolic profile. In contrast,
the microinsert coil requires a hysteroscopic or laparoscopic
procedure for insertion in the fallopian tubes. Like vasectomy
or bilateral tubal ligation, these procedures are not believed to
affect glucose metabolism.
Conclusion
GDM presents a unique opportunity to modify future disease
risk for women and their offspring. Women receive closer
medical attention than at other times in their adult lives, they
are highly motivated to improve the health of their children,
and women’s health and their children’s health are tightly
linked. In order to successfully reduce the risk of future
disease, postpartum women with histories of GDM need:
(i) postpartum screening to identify previously undiagnosed
diabetes, (ii) postpartum screening to identify women
potentially eligible for lifestyle and metformin intervention,
(iii) effective family planning to minimize the diabetes risk
associated with an additional pregnancy as well as risk of
another GDM pregnancy, (iv) lifestyle modification to reduce
chronic disease risk and (v) lifestyle modification to reduce risk
of another GDM pregnancy. Regarding the last two points,
the effectiveness of particular lifestyle modification programs
in newly postpartum has not yet been demonstrated. Further
investigation of which types of programs benefit which women
and identification of women at particularly high risk for
diabetes conversion are needed to increase the effectiveness
of any prevention efforts.
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